Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes

To examine the effect of pioglitazone on epicardial (EAT) and paracardial adipose tissue (PAT) and measures of diastolic function and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM).

[1]  M. Chiriacò,et al.  Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function , 2022, Diabetes, obesity & metabolism.

[2]  A. Mengozzi,et al.  Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug , 2021, Cardiovascular Diabetology.

[3]  M. Jensen,et al.  Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes , 2019, Cardiovascular Diabetology.

[4]  P. Schnohr,et al.  Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes , 2019, Diabetes, obesity & metabolism.

[5]  R. DeFronzo,et al.  Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes , 2019, Diabetes & vascular disease research.

[6]  Jeroen J. Bax,et al.  Impact of Epicardial Adipose Tissue, Left Ventricular Myocardial Fat Content, and Interstitial Fibrosis on Myocardial Contractile Function , 2018, Circulation. Cardiovascular imaging.

[7]  R. DeFronzo,et al.  Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control , 2018, Endocrinology, diabetes & metabolism.

[8]  Rachael Williams,et al.  Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study , 2018, BMJ Open Diabetes Research & Care.

[9]  Y. van der Graaf,et al.  Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials , 2017, Cardiovascular Diabetology.

[10]  P. Iozzo,et al.  Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes , 2017, Diabetes Care.

[11]  P. Sbraccia,et al.  Epicardial adipose tissue: at the heart of the obesity complications , 2017, Acta Diabetologica.

[12]  C. Viscoli,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[13]  S. Rabkin.  The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta-analysis. , 2014, Metabolic syndrome and related disorders.

[14]  J. M. Suh,et al.  PPARγ signaling and metabolism: the good, the bad and the future , 2013, Nature Medicine.

[15]  P. Marraccini,et al.  The role of cardiac fat in insulin resistance , 2012, Current opinion in clinical nutrition and metabolic care.

[16]  Eugenio Picano,et al.  Pericardial rather than epicardial fat is a cardiometabolic risk marker: an MRI vs echo study. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[17]  D. Dey,et al.  Increase in epicardial fat volume is associated with greater coronary artery calcification progression in subjects at intermediate risk by coronary calcium score: a serial study using non-contrast cardiac CT. , 2011, Atherosclerosis.

[18]  Devjit Tripathy,et al.  Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.

[19]  S. Bahouth,et al.  Inflammatory Genes in Epicardial Fat Contiguous With Coronary Atherosclerosis in the Metabolic Syndrome and Type 2 Diabetes , 2011, Diabetes Care.

[20]  R. DeFronzo.  Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 , 2010, Diabetologia.

[21]  L. J. Hardies,et al.  Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. , 2010, The Journal of clinical endocrinology and metabolism.

[22]  E. Ferrannini,et al.  Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. , 2009, American journal of physiology. Endocrinology and metabolism.

[23]  Jeroen J. Bax,et al.  Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus , 2009, Circulation.

[24]  Udo Hoffmann,et al.  Pericardial Fat, Intrathoracic Fat, and Measures of Left Ventricular Structure and Function: The Framingham Heart Study , 2009, Circulation.

[25]  M. Prentki,et al.  Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial , 2009, Diabetologia.

[26]  Udo Hoffmann,et al.  Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. , 2008, European heart journal.

[27]  Y. Miyazaki,et al.  Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients , 2008, Diabetes, obesity & metabolism.

[28]  Mathias Prokop,et al.  Relation of epicardial and pericoronary fat to coronary atherosclerosis and coronary artery calcium in patients undergoing coronary angiography. , 2008, The American journal of cardiology.

[29]  Udo Hoffmann,et al.  Pericardial Fat, Visceral Abdominal Fat, Cardiovascular Disease Risk Factors, and Vascular Calcification in a Community-Based Sample: The Framingham Heart Study , 2008, Circulation.

[30]  E. Abel,et al.  Diabetic cardiomyopathy revisited. , 2007, Circulation.

[31]  H. Sacks,et al.  Human epicardial adipose tissue: a review. , 2007, American heart journal.

[32]  L. J. Hardies,et al.  Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus , 2007, Diabetologia.

[33]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[34]  P. Iozzo,et al.  Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. , 2006, The Journal of clinical endocrinology and metabolism.

[35]  Y. Miyazaki,et al.  The Effect of Pioglitazone on the Liver , 2006, Diabetes Care.

[36]  F. Leonetti,et al.  Epicardial adipose tissue and insulin resistance in obese subjects. , 2005, The Journal of clinical endocrinology and metabolism.

[37]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[38]  R. DeFronzo,et al.  Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. , 2004, The Journal of clinical endocrinology and metabolism.

[39]  F. Leonetti,et al.  Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. , 2003, The Journal of clinical endocrinology and metabolism.

[40]  A. Butte,et al.  Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Z. Bloomgarden.  Obesity, hypertension, and insulin resistance. , 2002, Diabetes care.

[42]  J. Hardies,et al.  Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. , 2002, The Journal of clinical endocrinology and metabolism.

[43]  M. Matsuda,et al.  Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. , 2001, Diabetes care.

[44]  任艳,et al.  胰岛素增敏剂一Thiazolidinediones研究现状 , 2000 .

[45]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[46]  C. Morales,et al.  Epicardial Adipose Tissue in Cardiovascular Disease. , 2019, Advances in experimental medicine and biology.

[47]  P. Toth.  The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA) , 2010 .

[48]  Jeroen J. Bax,et al.  Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus. , 2010, The Journal of clinical endocrinology and metabolism.

[49]  R. Mosteller.  Simplified calculation of body-surface area. , 1987, The New England journal of medicine.